Who are Atea Pharmaceuticals, Inc.'s main suppliers?

Atea Pharmaceuticals, Inc. (AVIR) key suppliers include: MERCK-CO-INC, MSD-INTERNATIONAL-GMBH. View the full supplier network at chainsifter.com/chain/AVIR.

Who are Atea Pharmaceuticals, Inc.'s major customers?

Atea Pharmaceuticals, Inc. (AVIR) key customers include: Gilead Sciences, Inc., Gilead Sciences, Inc., Merck & Co., Inc., Merck & Co., Inc.. View the full customer network at chainsifter.com/chain/AVIR.

What sector is Atea Pharmaceuticals, Inc. in?

Atea Pharmaceuticals, Inc. (AVIR) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Atea Pharmaceuticals, Inc. (AVIR): 8 Verified Supply Chain Relationships

2Suppliers

4Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Atea Pharmaceuticals, Inc. (AVIR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

9Total relationships

2Distinct source URLs

5High confidence

0.824Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Atea Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
MERCK-CO-INC	MERCK-CO-INC	92%	In December 2021, the Company entered into a license agreement with MSD International GmbH, an affiliate of Merck & Co, Inc. for the development, manufacture and commercialization of ruzasvir.
MSD-INTERNATIONAL-GMBH	MSD-INTERNATIONAL-GMBH	92%	In December 2021, the Company entered into a license agreement with MSD International GmbH, an affiliate of Merck & Co, Inc. for the development, manufacture and commercialization of ruzasvir.

Atea Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
GILD	Gilead Sciences, Inc.	72%	Reciprocal relationship from GILD graph: Reciprocal relationship from AVIR graph: ed to incur substantial expenses in connection with future environmental compliance or remediation activities, in whi…
GILD	Gilead Sciences, Inc.	72%	ed to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our developmen…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from AVIR graph: Reciprocal relationship from MRK graph: Reciprocal relationship from AVIR graph: Reciprocal relationship from MRK grap…
MRK	Merck & Co., Inc.	72%	rary in in vitro and in vivo studies to assess the antiviral activity and other properties of such compounds against other RNA viral infections. In all our discovery and preclinical efforts, we asses…

Atea Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
AVIR-DEBT-7994	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2020-12-31.
AVIR-DEBT	Debt stack $634,000	90%	Market cache reports total debt of $634,000.

Atea Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Atea Pharmaceuticals, Inc..

Atea Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
AVIR-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 129 tracked holders.

Atea Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ENLV	Enlivex Ltd.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
CRIS	Curis, Inc.	100.00	2
BMY	Bristol-Myers Squibb Company	100.00	2
GDTC	CytoMed Therapeutics Limited	100.00	2
PSNL	Personalis, Inc.	100.00	2
CAH	Cardinal Health, Inc.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
EVAX	Evaxion A/S	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
GILD	Gilead Sciences, Inc.	100.00	1	['customer']
CABA	Cabaletta Bio, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
ADAG	Adagene Inc.	100.00	2
IMMP	Immutep Limited	100.00	2
IBRX	ImmunityBio, Inc.	100.00	2

Atea Pharmaceuticals, Inc. Supply Chain